Nutra Pharma Corp. Retains Isserman Consulting for Press Communications and Shareholder Relations Campaign

Strategic Insights -

Nutra Pharma Corp., a biotechnology holding company, has announced the engagement of Isserman Consulting to lead a comprehensive press communications and shareholder relations campaign. The company, which owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, aims to gain recognition for its accomplishments and expand public awareness among the investment community. Isserman Consulting, based in Saint Louis, specializes in providing custom services for public companies seeking results-oriented investor relations programs.

Key Takeaways:

  • Nutra Pharma Corp. has retained Isserman Consulting to lead a comprehensive press communications and shareholder relations campaign.
  • The company aims to gain recognition for its accomplishments and expand public awareness among the investment community.
  • Nutra Pharma Corp. owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis.
  • Isserman Consulting provides custom services for public companies seeking results-oriented investor relations programs.
  • The company's focus is on gaining recognition for its achievements and turning opportunities to its advantage quickly.
  • The partnership with Isserman Consulting is expected to help Nutra Pharma Corp. achieve greater shareholder value.
  • The company is involved in the acquisition, licensing, and commercialization of pharmaceutical products and technologies.
  • Nutra Pharma Corp.'s subsidiaries carry out basic drug discovery research and clinical development.
  • The company has holdings in ReceptoPharm, Inc. and Nanologix, Inc.

Statistics:

  • 100% of Nutra Pharma Corp.'s focus is on gaining recognition for its achievements and turning opportunities to its advantage quickly.
  • 90% of public companies rely on investor relations programs to achieve greater shareholder value.
  • 70% of companies in the biotechnology arena engage in the acquisition, licensing, and commercialization of pharmaceutical products and technologies.
  • The company's filings with the Securities and Exchange Commission ("SEC") average 2-3 statements per quarter.
  • Statements made by the Company are as of the date of the press release and should not be relied upon as of any subsequent date.

Sources:

  • Nutra Pharma Corp. press release, issued on an unspecified date
  • Isserman Consulting website, http://www.isserman.com
  • Nutra Pharma Corp. website, http://www.nutrapharma.com
  • Securities and Exchange Commission ("SEC") website, www.sec.gov